首页> 外文期刊>Surgical Endoscopy >Laparoscopic radiofrequency thermal ablation for unusual hepatic tumors: operative indications and outcomes.
【24h】

Laparoscopic radiofrequency thermal ablation for unusual hepatic tumors: operative indications and outcomes.

机译:腹腔镜射频热消融治疗罕见肝肿瘤:手术指征和预后。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: There is increasing experience with laparoscopic radiofrequency ablation for the treatment of patients with hepatic metastasis from colorectal and neuroendocrine cancer and those with hepatocellular cancer. Little is known about the outcomes for patients with other tumor types. METHODS: Between January 1996 and March 2005, 517 patients with 1,500 primary and metastatic liver tumors underwent laparoscopic radiofrequency ablation. Among these, 53 patients (10%) had cancers other than the colorectal, neuroendocrine, or hepatocellular types including sarcoma (n = 18), breast cancer (n = 10), esophagus cancer (n = 4), melanoma (n = 4), lung cancer (n = 3), ovarian cancer (n = 2), pancreas cancer (n = 2), unknown primary cancer (n = 2), cholangiocarcinoma (n = 2), rectal squamous cancer (n = 2), renal cancer (n = 2), papillary thyroid cancer (n = 1), and hemangioendothelioma (n = 1). Unlike the criteria for treatment of the more usual tumor types, these patients had a diagnosis of liver-exclusivedisease, as diagnosed by preoperative imaging. They also had failed chemotherapy. RESULTS: The 53 patients underwent ablation of 192 lesions, with 8 patients undergoing repeat treatment. The hospital stay averaged 1 day, and there was no 30-day mortality. Complications included one postoperative hemorrhage, one liver abscess, and one wound infection. Tumors recurred locally for 17% of the lesions over a mean follow-up period of 24 months. The overall median survival was 33 months for the whole series, more than 51 months for breast cancer, and 25 months for sarcoma. CONCLUSION: Laparoscopic radiofrequency ablation can safely and effectively treat hepatic metastasis of these unusual tumor types. The authors believe that this heterogeneous group of patients, selected for their unusual presentation of liver-exclusive disease, may benefit from cytoreduction of their tumor by laparoscopic radiofrequency ablation when other treatment methods have failed.
机译:背景:腹腔镜射频消融治疗结直肠癌和神经内分泌癌以及肝细胞癌的肝转移患者的经验越来越多。对于其他类型肿瘤患者的预后知之甚少。方法:1996年1月至2005年3月,对517例1,500例原发性和转移性肝肿瘤患者进行了腹腔镜射频消融。其中53例(10%)患者患有结直肠,神经内分泌或肝细胞类型以外的癌症,包括肉瘤(n = 18),乳腺癌(n = 10),食道癌(n = 4),黑素瘤(n = 4 ),肺癌(n = 3),卵巢癌(n = 2),胰腺癌(n = 2),未知原发癌(n = 2),胆管癌(n = 2),直肠鳞状癌(n = 2) ,肾癌(n = 2),甲状腺乳头状癌(n = 1)和血管内皮瘤(n = 1)。与更常见的肿瘤类型的治疗标准不同,这些患者被术前影像学诊断为肝脏排斥性疾病。他们也化疗失败。结果:53例患者接受了192例病灶的消融,其中8例患者接受了重复治疗。住院时间平均为1天,没有30天死亡。并发症包括1例术后出血,1例肝脓肿和1例伤口感染。在平均24个月的随访期内,肿瘤在17%的病变中局部复发。整个系列的总体中位生存期为33个月,乳腺癌超过51个月,肉瘤为25个月。结论:腹腔镜射频消融术可以安全有效地治疗这些罕见肿瘤类型的肝转移。作者认为,这些异类患者因其不常见的肝脏排他性疾病表现而选定,当其他治疗方法均无效时,可通过腹腔镜射频消融术从肿瘤的细胞减少中受益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号